Biomea Fusion, Inc.

    • Market Cap $294.96M
    • PE -2
    • Debt $NaN
    • Cash $88.32M
    • EV $NaN
    • FCF -$113.02M

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$144.01M
    EBIT-$151.32M
    ROE-190%
    ROA-137%
    FCF-$113.02M
    Equity$75.97M
    Growth Stability1
    PE-2.05
    PB3.88
    P/FCF-2.61
    Price/Cash0.3
    Equity CAGR116%
    Earnings Growth YoY15%
    Earnings Growth QoQ-12%
    Equity CAGR 5Y116%
    Equity CAGR 3Y-13%
    Market Cap$294.96M
    Assets$110.42M
    Cash$88.32M
    Shares Outstanding36.01M
    Working Capital66.03M
    Current Ratio3.39
    Shares Growth 3y14%
    Equity Growth QoQ-27%
    Equity Growth YoY-62%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

    SEC Filings

    Direct access to Biomea Fusion, Inc. (BMEA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31

    Sector Comparison

    How does Biomea Fusion, Inc. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Biomea Fusion, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Biomea Fusion, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Biomea Fusion, Inc..

    = -$1.1B
    012345678910TV
    fcf-$113M-$113M-$113M-$113M-$113M-$113M-$113M-$113M-$113M-$113M-$113M-$1.1B
    DCF-$103M-$93M-$85M-$77M-$70M-$64M-$58M-$53M-$48M-$44M-$436M
    Value-$1.1B

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/201912/202012/202112/202212/2023TTM
    Net Margins------
    ROA--9%-22%-65%-63%-137%
    ROE--103%-23%-75%-69%-190%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/201912/202012/202112/202212/2023TTM
    Debt over FCF------
    Debt over Equity------
    Growth Stability-----1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/201912/202012/202112/202212/2023CAGR 5Y
    Revenue YoY growth------
    Earnings YoY growth-344%681%97%43%-
    Equity YoY growth--25K%3K%-39%56%116%
    FCF YoY growth--756%64%58%-